COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE
OPENING OF A CALL FOR TENDER TO PROVIDE A CONTINUATION OR SALE PLAN IN THE FRAME OF REOGANIZATION PROCEEDINGS
The deadline for submission of all tenders is January 10th, 2020 before 04:00pm
Paris and Boston, December 6th, 2019 - 05h45pm CET - Neovacs (Euronext Growth Paris: ALNEV) announces the launch of a call for tender opened from now until January 10th, 2020 before 4:00 pm, to provide a continuation plan through partners or investors (articles L.626-1 and L.626-3 of the French Commercial code) or a sale plan by one or more buyers (Articles L.642-1 et seq. of the French Commercial Code).
Candidates are invited to submit their offer before January 10th, 2020 at 04:00pm at the following law office: SELARL 2M and associates, to Maître Carole Martinez, judicial administrator, 22 rue de l'Arcade 75008 Paris, France. Email: a.dekoninck@aj-2m.com
Access to information for auditing the company (electronic data room), will be granted upon reasoned written request to the judicial administrator along with the appropriate financial, industrial or commercial capacity proofs.
As a reminder, on November 26th, 2019 the Commercial Court of Paris decided the opening of reorganization proceedings of the company, as requested by Neovacs (press release of November 27th, 2019).
Neovacs is a French biotech company listed on Euronext Growth since 2010. The Company is focused on therapeutic vaccines targeting the treatment of autoimmune diseases. Its innovative technology named Kinoid, patented until 2038, induces a polyclonal immune response, applicable in several indications. Neovacs has developed the IFNa KINOID to treat lupus in a clinical phase IIb study, the main study is now ended and the full results have been presented at the 13th international Lupus Congress 2019. The Company also carries out preclinical work on IL-4/ IL-13 Kinoid, another therapeutic vaccine for the treatment of allergies. The aim of this "KINOID approach" is to enable patients to better cope with a life-long treatment that would be more effective. For more information: www.neovacs.fr
Attachment
- PR NEOVACS 061219 vdef (https://ml-eu.globenewswire.com/Resource/Download/196d954c-6921-480e-ae11-5d1247cf02d8)
